FDA Warning Letter · #718739
GenoGenix LLC — FDA Warning Letter (January 20, 2026)
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026
Summary
- Company
- GenoGenix LLC
- Letter number
- #718739
- Issue date
- January 20, 2026
- Subject
- Compounding Pharmacy/Adulterated Drug Products
What FDA cited
the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C.
From the letter
Read full letter on FDA.gov →Quoted verbatim from the FDA warning letter dated January 20, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER) United States
Source: U.S. Food and Drug Administration. Quoted as a verbatim excerpt for editorial commentary; no claim is made beyond what FDA itself has published. The full letter is available at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026
What FDA warning letters mean
A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.
A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.
For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.
Other warning letters in our database
- Novo Nordisk Inc. — March 5, 2026
- Join Josie — February 20, 2026
- FitRx — February 20, 2026
- Kin Meds — February 20, 2026
- Measured — February 20, 2026
Editorial Disclaimer
FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.